EMVI—European Malaria Vaccine Initiative

EMVI was established in 1998 by the European Commission and interested European Union Member States to address structural deficiencies in publicly funded malaria vaccine development. EMVI’s aim is to provide a mechanism to accelerate the development of malaria vaccines in Europe and in endemic countries.

MVI—Malaria Vaccine Initiative

MVI was created in 1999 with a grant from the Bill & Melinda Gates Foundation to PATH (Program for Appropriate Technology in Health). MVI’s mission is to accelerate the development of promising malaria vaccines, and to ensure their availability and accessibility in the developing world. MVI works with other vaccine programs, vaccine development partners, and the Global Alliance for Vaccines and Immunization (GAVI) to explore commercialization, procurement, and delivery strategies that will maximize public health sector availability in the countries most affected by malaria.

MARA—Mapping Malaria Risk in Africa

MARA is a pan-African collaborative network, initiated in 1997, to collect, collate, validate, and manage all available malaria data from Africa, and to map the distribution, intensity, and seasonality of malaria on the continent. Its primary objective is to support African control initiatives.

MMV—Medicines for Malaria Venture

MMV is a not-for-profit public-private partnership, launched in 1999. Its goal is to develop and manage a portfolio of malaria drug discovery and development projects that will yield one new product every five years appropriate for (and affordable to) malaria-endemic countries. The initiative arose from discussions between WHO and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). Early partners were the Rockefeller Foundation, the World Bank, the Swiss Agency for Development and